SPYGLASS PHARMA INC (SGP) Fundamental Analysis & Valuation

NASDAQ:SGP • US85220G1094

Current stock price

24.45 USD
-0.07 (-0.29%)
Last:

This SGP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SGP Profitability Analysis

1.1 Basic Checks

  • In the past year SGP has reported negative net income.
  • In the past year SGP has reported a negative cash flow from operations.
SGP Yearly Net Income VS EBIT VS OCF VS FCFSGP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of SGP (-68.82%) is worse than 74.87% of its industry peers.
  • The Return On Equity of SGP (-75.44%) is worse than 61.78% of its industry peers.
Industry RankSector Rank
ROA -68.82%
ROE -75.44%
ROIC N/A
ROA(3y)-127.9%
ROA(5y)N/A
ROE(3y)-208.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGP Yearly ROA, ROE, ROICSGP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • SGP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGP Yearly Profit, Operating, Gross MarginsSGP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. SGP Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for SGP remains at a similar level compared to 1 year ago.
  • There is no outstanding debt for SGP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SGP Yearly Shares OutstandingSGP Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 2025 10M 20M 30M
SGP Yearly Total Debt VS Total AssetsSGP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 45.79 indicates that SGP is not in any danger for bankruptcy at the moment.
  • SGP has a Altman-Z score of 45.79. This is amongst the best in the industry. SGP outperforms 93.72% of its industry peers.
  • SGP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 45.79
ROIC/WACCN/A
WACCN/A
SGP Yearly LT Debt VS Equity VS FCFSGP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 12.67 indicates that SGP has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 12.67, SGP belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
  • SGP has a Quick Ratio of 12.67. This indicates that SGP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 12.67, SGP belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.67
Quick Ratio 12.67
SGP Yearly Current Assets VS Current LiabilitesSGP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SGP Growth Analysis

3.1 Past

  • The earnings per share for SGP have decreased strongly by -36.71% in the last year.
EPS 1Y (TTM)-36.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.74% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.04%
EPS Next 2Y-3.24%
EPS Next 3Y-4.74%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SGP Yearly EPS VS EstimatesSGP Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. SGP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SGP. In the last year negative earnings were reported.
  • Also next year SGP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGP Price Earnings VS Forward Price EarningsSGP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGP Per share dataSGP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • SGP's earnings are expected to decrease with -4.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.24%
EPS Next 3Y-4.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGP Dividend Analysis

5.1 Amount

  • SGP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SGP Fundamentals: All Metrics, Ratios and Statistics

SPYGLASS PHARMA INC

NASDAQ:SGP (4/21/2026, 4:30:03 PM)

24.45

-0.07 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26
Earnings (Next)N/A
Inst Owners76.68%
Inst Owner ChangeN/A
Ins Owners3.53%
Ins Owner Change83.94%
Market Cap817.36M
Revenue(TTM)N/A
Net Income(TTM)-79.74M
Analysts88.89
Price Target45.9 (87.73%)
Short Float %2.98%
Short Ratio5.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.73
P/tB 7.73
EV/EBITDA N/A
EPS(TTM)-2.5
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.96
OCFYN/A
SpS0
BVpS3.16
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -68.82%
ROE -75.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-127.9%
ROA(5y)N/A
ROE(3y)-208.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 128.92%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.67
Quick Ratio 12.67
Altman-Z 45.79
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)346.31%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.71%
EPS Next Y8.04%
EPS Next 2Y-3.24%
EPS Next 3Y-4.74%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.06%
EBIT Next 3Y-14.31%
EBIT Next 5YN/A
FCF growth 1Y-43.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.46%
OCF growth 3YN/A
OCF growth 5YN/A

SPYGLASS PHARMA INC / SGP Fundamental Analysis FAQ

What is the fundamental rating for SGP stock?

ChartMill assigns a fundamental rating of 3 / 10 to SGP.


Can you provide the valuation status for SPYGLASS PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to SPYGLASS PHARMA INC (SGP). This can be considered as Overvalued.


Can you provide the profitability details for SPYGLASS PHARMA INC?

SPYGLASS PHARMA INC (SGP) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for SGP stock?

The Earnings per Share (EPS) of SPYGLASS PHARMA INC (SGP) is expected to grow by 8.04% in the next year.